Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018

Sneha Suresh, Julia Upton, Michael Green, Anne Pham-Huy, Klara M. Posfay-Barbe, Marian G. Michaels, Karina A. Top, Yaron Avitzur, Catherine Burton, Pearlie Pao Ee Chong, Lara Danziger-Isakov, Anne I. Dipchand, Diane Hébert, Deepali Kumar, Shaun K. Morris, Nadya Nalli, Vicky Lee Ng, Sarah Kogan Nicholas, Joan L. Robinson, Melinda SolomonBruce Tapiero, Anita Verma, Jolan E. Walter, Upton D. Allen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

Original languageEnglish (US)
Article numbere13571
JournalPediatric Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Vaccines
Pediatrics
Transplants
Viral Vaccines
Vaccination
Transplantation Immunology
Herd Immunity
Measles-Mumps-Rubella Vaccine
Mycophenolic Acid
Kidney
Attenuated Vaccines
Liver
Viral Load
Human Herpesvirus 4
Disease Outbreaks
Communicable Diseases

Keywords

  • immunization
  • live vaccinations
  • measles-mumps-rubella vaccine
  • solid organ transplant
  • varicella-zoster vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Suresh, S., Upton, J., Green, M., Pham-Huy, A., Posfay-Barbe, K. M., Michaels, M. G., ... Allen, U. D. (Accepted/In press). Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. Pediatric Transplantation, [e13571]. https://doi.org/10.1111/petr.13571

Live vaccines after pediatric solid organ transplant : Proceedings of a consensus meeting, 2018. / Suresh, Sneha; Upton, Julia; Green, Michael; Pham-Huy, Anne; Posfay-Barbe, Klara M.; Michaels, Marian G.; Top, Karina A.; Avitzur, Yaron; Burton, Catherine; Chong, Pearlie Pao Ee; Danziger-Isakov, Lara; Dipchand, Anne I.; Hébert, Diane; Kumar, Deepali; Morris, Shaun K.; Nalli, Nadya; Ng, Vicky Lee; Nicholas, Sarah Kogan; Robinson, Joan L.; Solomon, Melinda; Tapiero, Bruce; Verma, Anita; Walter, Jolan E.; Allen, Upton D.

In: Pediatric Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Suresh, S, Upton, J, Green, M, Pham-Huy, A, Posfay-Barbe, KM, Michaels, MG, Top, KA, Avitzur, Y, Burton, C, Chong, PPE, Danziger-Isakov, L, Dipchand, AI, Hébert, D, Kumar, D, Morris, SK, Nalli, N, Ng, VL, Nicholas, SK, Robinson, JL, Solomon, M, Tapiero, B, Verma, A, Walter, JE & Allen, UD 2019, 'Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018', Pediatric Transplantation. https://doi.org/10.1111/petr.13571
Suresh, Sneha ; Upton, Julia ; Green, Michael ; Pham-Huy, Anne ; Posfay-Barbe, Klara M. ; Michaels, Marian G. ; Top, Karina A. ; Avitzur, Yaron ; Burton, Catherine ; Chong, Pearlie Pao Ee ; Danziger-Isakov, Lara ; Dipchand, Anne I. ; Hébert, Diane ; Kumar, Deepali ; Morris, Shaun K. ; Nalli, Nadya ; Ng, Vicky Lee ; Nicholas, Sarah Kogan ; Robinson, Joan L. ; Solomon, Melinda ; Tapiero, Bruce ; Verma, Anita ; Walter, Jolan E. ; Allen, Upton D. / Live vaccines after pediatric solid organ transplant : Proceedings of a consensus meeting, 2018. In: Pediatric Transplantation. 2019.
@article{f2919947e95045e4b659cc56c42d7279,
title = "Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018",
abstract = "Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.",
keywords = "immunization, live vaccinations, measles-mumps-rubella vaccine, solid organ transplant, varicella-zoster vaccine",
author = "Sneha Suresh and Julia Upton and Michael Green and Anne Pham-Huy and Posfay-Barbe, {Klara M.} and Michaels, {Marian G.} and Top, {Karina A.} and Yaron Avitzur and Catherine Burton and Chong, {Pearlie Pao Ee} and Lara Danziger-Isakov and Dipchand, {Anne I.} and Diane H{\'e}bert and Deepali Kumar and Morris, {Shaun K.} and Nadya Nalli and Ng, {Vicky Lee} and Nicholas, {Sarah Kogan} and Robinson, {Joan L.} and Melinda Solomon and Bruce Tapiero and Anita Verma and Walter, {Jolan E.} and Allen, {Upton D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/petr.13571",
language = "English (US)",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Live vaccines after pediatric solid organ transplant

T2 - Proceedings of a consensus meeting, 2018

AU - Suresh, Sneha

AU - Upton, Julia

AU - Green, Michael

AU - Pham-Huy, Anne

AU - Posfay-Barbe, Klara M.

AU - Michaels, Marian G.

AU - Top, Karina A.

AU - Avitzur, Yaron

AU - Burton, Catherine

AU - Chong, Pearlie Pao Ee

AU - Danziger-Isakov, Lara

AU - Dipchand, Anne I.

AU - Hébert, Diane

AU - Kumar, Deepali

AU - Morris, Shaun K.

AU - Nalli, Nadya

AU - Ng, Vicky Lee

AU - Nicholas, Sarah Kogan

AU - Robinson, Joan L.

AU - Solomon, Melinda

AU - Tapiero, Bruce

AU - Verma, Anita

AU - Walter, Jolan E.

AU - Allen, Upton D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

AB - Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

KW - immunization

KW - live vaccinations

KW - measles-mumps-rubella vaccine

KW - solid organ transplant

KW - varicella-zoster vaccine

UR - http://www.scopus.com/inward/record.url?scp=85071930524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071930524&partnerID=8YFLogxK

U2 - 10.1111/petr.13571

DO - 10.1111/petr.13571

M3 - Article

C2 - 31497926

AN - SCOPUS:85071930524

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

M1 - e13571

ER -